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ABSTRACT 
 
Background: Vulvovaginal candidiasis (VVC) is an important health problem caused by Candida spp. The aim of 
this study was molecular identification, phylogenetic analysis, and evaluation of antifungal susceptibility of non-
albicans Candida isolates from VVC. Methods: Vaginal secretion samples were collected from 550 vaginitis 
patients at Sayyad Shirazi Medical and Educational Center of Gorgan (Golestan Province, Iran) from May to 
October 2015. Samples were analyzed using conventional mycological and molecular approaches. Clinical isolates 
were analyzed with specific PCR using CGL primers, and the internal transcribed spacer region and the D1-D2 
domain of the large-subunit rRNA gene were amplified and sequenced. Susceptibility to amphotericin B, 
fluconazole, itraconazole, and clotrimazole was determined by the guidelines of the Clinical and Laboratory 
Standard Institute. Results: In total, 35 non-albicans Candida isolates were identified from VVC patients. The 
isolates included 27 strains of Candida glabrata (77.1%), 5 Candida krusei (Pichia kudriavzevii; 14.3%), 2 Candida 
kefyr (Kluyveromyces marxianus; 5.7%), and 1 Candida lusitaniae (Clavispora lusitaniae; 2.9%). The fungicides 
itraconazole and amphotericin B were effective against all species. One isolate of C. glabrata showed resistance to 
fluconazole and clotrimazole, and 26 isolates of C. glabrata indicated dose-dependent susceptibility to 
fluconazole. C. lusitaniae was susceptible in a dose-dependent manner to fluconazole and resistant to 
clotrimazole. Conclusions: Non-albicans Candida spp. are common agents of vulvovaginitis, and C. glabrata is the 
most common species in the tested patients. DOI: 10.22034/ibj.22.1.33    
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INTRODUCTION 
 
he incidence of vulvovaginal candidiasis (VVC) 
caused by non-albicans Candida spp. has 
increased considerably
[1,2]
. Based on evidence, 
about two-thirds of women worldwide have 
experienced at least one episode of VVC during their 
lifetime
[3]
 and some with recurrent episodes
[1]
. 
Recurrent episodes are more often caused by non-
albicans Candida spp. against which azole antifungal T 
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agents show low effectiveness
[4]
.  
Candida albicans is the major cause of 
vulvovaginitis, and Candida glabrata and Candida 
tropicalis appear to be the most common non-albicans 
Candida species involved in this disease
[2,4-6]
. 
Identification of many species of Candida by 
traditional methods is a challenge and is sometimes 
imprecise, particularly for uncommon microorganisms. 
Sequence analysis of the internal transcribed spacer 
(ITS) region of the rRNA gene and the D1-D2 domain 
of the large-subunit rRNA gene as well as PCR-RFLP 
on the ITS region have been used extensively for 
identification of fungal pathogens
[7-11]
.  
Minimal inhibitory concentrations (MIC) of azoles 
against some strains of non-albicans Candida species 
are high, due to intrinsic resistance
[12]
. The antifungal 
susceptibility of Candida spp. causing VVC 
varies
[12,13]
, and reliable identification and assessment 
of drug sensitivity of Candida vaginal isolates are of 
value in determining proper treatment. The aim of this 
study was molecular identification, phylogenetic 
analysis, and evaluation of antifungal susceptibility of 
non-albicans Candida isolates causing VVC.   
 
 
MATERIALS AND METHODS 
 
Patients and specimens collection 
This study was conducted on 550 non-pregnant 
vaginitis patients referred to Sayyad Shirazi Medical 
and Educational Center of Gorgan (Golestan, Iran) 
from May to October 2015. Non-pregnant patients 
were entered to the study by a simple random sampling 
method. A questionnaire was completed for each 
patient about their age, the medical condition (recent 
antibiotic or antifungal therapy, urinary tract infections, 
immunodeficiency, diabetes, experiencing at least one 
episode or recurrent episodes of VVC), and other 
conditions. Specimens were obtained from vaginal 
mucosal discharge with a sterile cotton swab. The 
research protocol was approved by the Ethics 
Committee of Iran University of Medical Sciences 
(Tehran, Iran), under Ethics Committee number 93-04-
198-25289. 
   
Yeast identification 
 Microscopic examination was carried out to 
distinguish yeast forms or pseudohyphae. All samples 
were cultured on CHROMagar Candida (CHROMagar, 
France) for identification of mixed infections of 
Candida spp.
[14]
. The isolates were identified by 
carbohydrate assimilation method using API 20C AUX 
system (Biomérieux, France)
[15]
. 
 
DNA extraction 
A single colony of each clinical isolate from 
CHROMagar Candida was subcultured on yeast extract 
peptone dextrose agar and incubated at 37 °C for 24-48 
h. Genomic DNA was extracted from yeast cultures 
using the Qiagen DNA tissue kit (Germany). The 
extracted DNA was stored at -20 °C for further use. 
 
Specific PCR 
All clinical isolates with mauve, pink, or white 
colonies on CHROMagar Candida as well as C. 
glabrata CBS 138, as the reference strain, were 
analyzed by C. glabrata-specific PCR with CGL1-(5´-
TTA TCA CAC GAC TCG ACA CT-3´) and CGL2- 
(5´-CCC ACA TAC TGA TAT GGC CTA CAA-3´)
[7]
 
primers.  The PCR thermal cycles were as follows: an 
initial denaturation at 96 °C for 5 min followed by 40 
cycles of 30 s at 94 °C, 30 s at annealing temperature  
of 58 °C and 30 s at 72 °C.  A final extension of 15 
min at 72 °C was included at the end of PCR cycles.   
 
Amplification and sequencing of ITS and D1-D2 
regions 
The universal primers ITS1 (5´-TCC GTA GGT 
GAA CCT GCG G -3´) and ITS4 (5´-TCC TCC GCT 
TAT TGA TAT GC-3´)
[7]
 were used to amplify the 
ITS1-5.8S-ITS2 region (annealing temperature 56 °C). 
Also, D1-D2 domain of 26S ribosomal RNA was 
amplified with NL1 (5´-GCA TAT CAA TAA GCG 
GAG GAA AAG-3´) and NL4 (5´- GGT CCG TGT 
TTC AAG ACG G-3´)
[16]
 primers by the following 
profile: 98 °C (5 min), 35 cycles of 98 °C (30 s), 
annealing temperature 60 °C (30 s), and 72 °C (30 s), 
followed by a final extension of 72 °C (5 min). The 
PCR products were sequenced by Macrogen (Korea). 
The resulting sequences were analyzed and compared 
with the reference data available from the GenBank 
database using the BLAST sequence search tool 
(http://www.ncbi.nlm.nih.gov/BLAST), and the results 
were submitted to the GenBank.  
 
Phylogenetic analysis 
The sequencing results of the D1-D2 and the ITS 
domains were analyzed and compared with the 
reference strains by neighbor-joining method using 
MEGA 7 (TreeView software).   
  
Antifungal drug susceptibility testing 
Tests of susceptibility to amphotericin B, 
fluconazole, clotrimazole, and itraconazole (Sigma, 
Germany) were conducted according to the Clinical 
and Laboratory Standards Institute (CLSI) guidelines 
(document M27-S3 and S4)
[17,18]
. C. glabrata CBS 138 
was used as the reference strain, and all tests were 
duplicated. 
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    Table 1. Non-albicans Candida isolates and age distribution 
of vulvovaginal candidiasis patients 
 
 
 
Ages (y) 
 
 
Candida spp. 
 
 C. 
glabrata 
C. 
krusei 
C. 
kefyr 
C. 
lusitaniae 
<20  6 3 1 - 
20-29  10 2 1 - 
30-39  11 - - 1 
 
 
 
RESULTS 
 
Patients 
A total of 550 vaginal specimens of non-pregnant 
vaginitis patients were studied. Individuals with 
conditions such as infection by Trichomonas vaginalis, 
Mycoplasma urealyticum, or Chlamydia, as well as 
bacterial vaginosis or vulval skin disease were 
excluded from the study. In addition, 122 (22.2%) non-
pregnant vaginitis patients showed VVC, and C. 
albicans isolates were identified in 87 (71.3%) VVC 
patients (data not shown). Non-albicans Candida 
isolates were found in 35 (28.7%) VVC patients aged 
19-39 years from Gorgan (Table 1). All patients were 
negative for diabetes, immunodeficiencies, or any 
chronic disease and were not taken any antifungal 
treatment.  
 
Yeast isolates 
Thirty-five isolates of non-albicans Candida were 
obtained from 550 vulvovaginitis patients: 27 C. 
glabrata (77.1%), 5 C. krusei (Pichia kudriavzevii; 
14.3%), 2 C. kefyr (Kluyveromyces marxianus; 5.7%), 
and 1 Candida lusitaniae (Clavispora lusitaniae; 2.9%) 
(Table 1).  
 
Amplification with specific primers 
The clinical isolates with mauve, pink, or white 
colonies on CHROMagar Candida and C. glabrata 
CBS 138 were analyzed with CGL1/2 specific primers, 
and the presence of the 423-bp fragment amplified with 
these primers confirmed those isolates identical to C. 
glabrata (Fig. 1).   
 
PCR amplification and sequencing of ITS region 
and D1-D2 domain  
PCR amplification of all clinical isolates with ITS1 
and ITS4 primers yielded the fragments of 350-880 bp. 
The ITS fragments of C. glabrata were ~500 to ~879 
bp (Fig. 2)
[8,10]
, while C. krusei, C. kefyr, and C. 
lusitaniae yielded the fragments of ~500, ~720, and 
~370 bp, respectively (Fig. 2)
[8]
. The ITS fragments of 
three clinical  C. glabrata isolates showing ~500 and 
~600 bp were compared to the reference data in  
the GenBank database using the BLAST. Three  
C. glabrata isolates showed partial sequences of ITS 
region (~500 and ~600 bp), while the complete 
sequences of ITS region of C. glabrata was ~879 bp, 
and the partial sequences and complete sequences were 
submitted to the GenBank (Table 2). The D1-D2 
region of the large-subunit rRNA gene amplified with 
NL1 and NL4 primers yielded the fragments of ~600 
bp (Fig. 3). The ITS and D1-D2 region sequences of 
non-albicans Candida clinical isolates were compared 
to the reference data in the GenBank database using 
BLAST (http://www.ncbi.nlm.nih.gov/BLAST). All 
clinical isolates were correctly determined to species 
level. The sequences were submitted to the GenBank 
under accession numbers KU845721, KU904424-26, 
KU992386-95, KX008737-53, and KX016018-21 
(Table 2). 
 
Phylogenetic trees 
The sequences of D1-D2 region were aligned for 
phylogenetic analysis. All C. glabrata strains showed 
100% identity with KU729149, KU729145, and 
KU729137 reference strains. C. krusei (Pichia 
kudriavzevii) indicated 100% similarity to KU729202 
and KU729201 reference strains. C. kefyr 
(Kluyveromyces marxianus) and C. lusitaniae 
(Clavispora lusitaniae) displayed 100% identity with 
KM279378 and KP070758 reference strains, 
respectively (Fig 4). Phylogenetic analysis of 
sequences corresponding to the ITS region 
demonstrated that all strains of the species were 
identical to the reference strains. C. glabrata strains 
showed similarity to KP675206, KP131703, 
KP675517, and LT577613 but C. krusei (Pichia 
kudriavzevii) to KX833111 and KX015902 reference 
 
 
 
 
 
Fig. 1. The genomic DNA of clinical isolates of Candida 
glabrata and C. glabrata CBS 138 were analyzed with PCR 
using CGL1/2 specific primers, and a 423-bp fragment 
produced. Isolates 1, 2, 3, 4, 5, 6, and 7, C. glabrata; S, C. 
glabrata CBS 138 (as standard); M, marker 100 bp; N, negative 
control. 
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Fig. 2. Amplification of genomic DNA from clinical isolates using ITS1 and ITS4 primers. Isolates 1 and 8, C. krusei (500 bp); 
isolates 2, 3, 4, 5, and 6, Candida glabrata producing an ~879-bp fragment; isolate 7, C. glabrata CBS 138 (as standard); isolate 9, 
Candida lusitaniae producing a ~370-bp fragment; M, marker 100 bp; N, negative control. 
 
 
           Table 2. Accession numbers of clinical isolates  
 
Clinical isolates Accession no. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. glabrata 
KU845721 
KU904426 
KU992388 
KU992389 
KU992390 
KU992391 
KU992392 
KU992393 
KU992394 
KU992395 
KX008737 
KX008738 
KX008739 
KX008740 
KX008741 
KX008744 
KX008745 
KX008748 
KX008749 
KX008750 
KX008751 
KX008752 
KX008753 
KX016018 
KX016019 
KX016020 
KX016021 
  
 
 
Pichia kudriavzevii 
(Candida krusei) 
 
KU904424 
KU992387 
KX008742 
KX008743 
KX008746 
 
Kluyveromyces 
marxianus(Candida kefyr) 
 
 KU992386 
KX008747 
 
Clavispora lusitaniae 
(Candida lusitaniae) 
 
KU904425  
strains. C. kefyr (Kluyveromyces marxianus) indicated 
identity with KJ849337 and KJ849335 reference 
strains, while C. lusitaniae (Clavispora lusitaniae) 
showed similarity to KP674503 reference strain (Fig. 
5). 
 
Antifungal drug susceptibility 
Results of susceptibility testing of the 35 non-
albicans Candida isolates showed one isolate of C. 
glabrata to be resistant to fluconazole (MIC ≥ 64 
µg/ml) and clotrimazole (MIC ≥ 4 µg/ml), and 26 
isolates of C. glabrata were susceptible to fluconazole 
(MIC ≤ 32 µg/ml) in a dose-dependent manner
[18]
. 
Single clinical isolate of C. lusitaniae showed dose-
dependent susceptibility to fluconazole (MIC = 16-32 
µg/ml) and resistant to clotrimazole (MIC = 2 
µg/ml)
[17]
. The MICs for one isolate of C. krusei were 
as follows: fluconazole ≤ 32 µg/ml and clotrimazole = 
2 µg/ml. Because the clinical isolates of C. krusei 
showed intrinsic resistant to fluconazole, and their 
MICs should not be interpreted using this scale; 
therefore, breakpoint was not provided by CLSI 
document M27-S4
[18]
. Itraconazole and amphotericin B 
were active against all of the isolates (Table 3).     
 
 
DISCUSSION 
 
This study revealed that non-albicans Candida spp., 
as important agents, are commonly associated with 
vulvovaginitis; C. glabrata is the second in rate of 
occurrence after C. albicans. Other investigations have 
found that C. glabrata and C. albicans to be the most 
common species isolated from VVC patients
[13,19,20]
. 
The overall proportion of non-albicans infection in 
vaginitis  has  been  reported  to  be high
[2]
. C. glabrata 
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Fig. 3. The D1-D2 region of clinical isolates amplified with 
NL1 and NL4 primers, yielded fragments ~600 bp. Isolate 1, C. 
glabrata CBS 138 (as standard); isolates 2, 3, 4, 5, 6, and 7,: 
Candida glabrata; M, marker 100 bp; N, negative control. 
 
 
 and C. tropicalis have also been found in the normal 
vaginal flora of women in China
[21]
. Infections caused 
by less common yeasts have been increasingly 
observed
[22]
, and identification of a variety of 
medically important yeast species by traditional 
approaches may be challenging. Molecular methods 
can improve discrimination of uncommon clinical 
isolates and closely related yeast species such as those 
in Candida complexes. Molecular diagnostics are also 
useful in carrying out large epidemiological studies of 
pathogenic yeasts. In this study, conventional methods 
and specific PCR with CGL primers were used for 
identification of C. glabrata. Sequencing the ITS and 
D1-D2 regions has proven to be a feasible method for 
the reliable identification of clinically important yeasts,  
 
 
 
Fig. 4. Molecular phylogenetic analysis using Neighbor-Joining method with sequences of D1-D2 domain. The evolutionary history 
was inferred using the Neighbor-Joining method. The percentage of replicate trees in which the associated taxa clustered together in 
the bootstrap test (1000 replicates) is shown next to the branches. Bootstrap values greater than 50% from 1000 replicates are indicated 
at the nodes. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. Evolutionary analyses were conducted in MEGA7. (A) Accession numbers of Candida glabrata isolated in this 
study and reference strains (KU729149, KU729145, and KU729137), (B) accession numbers of Kluyveromyces marxianus (Candida 
kefyr) isolated in this study and reference strain (KM279378), (C) Accession number of Clavispora lusitaniae (Candida lusitaniae) 
isolated in this study and reference strain (KP070758), (D) accession numbers of Pichia kudriavzevii (Candida krusei) isolated in this 
study (Table 1) and reference strains (KU729202 and KU72920). 
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Fig. 5. Molecular phylogenetic analysis using Neighbor-Joining method with sequences of ITS region. The evolutionary history was 
inferred using the Neighbor-Joining method. The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (1000 replicates) is shown next to the branches. Bootstrap values greater than 70% from 1000 replicates are indicated at 
the nodes. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. Evolutionary analyses were conducted in MEGA7.   
 
 
principally the C. glabrata complex (C. glabrata, C. 
bracarensis, and C. nivariensis)
[22,23]
 and the C. 
parapsilosis complex (C. parapsilosis, C. ortho-
psilosis, and C. metapsilosis)
[24]
. Richter et al.
[13]
 
reported that 173 of 593 yeast isolates from vaginitis 
patients were non-albicans Candida spp., and that C. 
albicans was the most frequent cause of vaginal 
candidiasis, followed by C. glabrata, C. parapsilosis, 
C. krusei, Saccharomyces cerevisiae, C. tropicalis, and 
C. lusitaniae
[13]
. Vijaya et al.
[25]
 showed that C. 
tropicalis is the major non-albicans species of Candida 
associated with vaginal candidiasis. Other studies in 
Iran introduced C. glabrata as the most important non-
albicans species in vaginal candidiasis patients
[19,20]
. 
Shi et al.
[26]
 demonstrated that C. albicans is the main 
cause of vaginal  candidiasis,  followed by C. glabrata,  
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      Table 3. Drug treatment susceptibility of Candida spp. isolated from vulvovaginal candidiasis patients  
 
 
Clinical isolates  
 Fluconazole  Itraconazole  Clotrimazole  Amphotericin B 
 S R S-DD  S R S-DD  S R S-DD  S R S-DD 
  n  n  n  n 
                 
C. glabrata (n = 27)  0 1 26  27 0 0  26 1 0  27 0 0 
C. krusei (n = 5)  --* -- --  5 0 0  4 1 0  5 0 0 
C. kefyr (n = 2)  2 0 0  2 0 0  2 0 0  2 0 0 
C. lusitaniae (n = 1)  0 0 1  1 0 0  0 1 0  1 0 0 
 
S, sensitive; R, resistant; S-DD, susceptible, dose-dependent; *Because of the clinical isolates of C. krusei showed intrinsically 
resistant to fluconazole; therefore, breakpoint is not provided by Clinical and Laboratory Standards Institute document M27-S4.  
 
 
C. tropicalis and C. parapsilosis in China. In the 
current study, C. glabrata was the most common 
species of non-albicans Candida. Candida spp., 
especially C. glabrata and C. albicans, represent a 
primary source of infection leading to bloodstream 
infections and to morbidity and mortality in severely 
affected and immune-compromised individuals
[12,27-29]
. 
Species C. krusei and  C. glabrata have been indicated. 
To be resistant or to have low susceptibility to azole 
drugs
[4,12]
. C. lusitaniae has also been shown to have 
resistance to amphotericin B, caspofungin, and 
azoles
[30]
. A study in Japan revealed that one of the 19 
C. glabrata clinical isolates of VVC patients showed 
resistance to fluconazole, and this isolate demonstrated 
cross-resistance to other antimycotic drugs tested
[31]
. 
Another study displayed that non-albicans isolates, 
particularly C. glabrata strains, were susceptible in a 
dose-dependent manner and were resistant to 
fluconazole
[13]
. Kalkanci et al.
[32]
 suggested that C. 
glabrata was the most vaginal isolate of non-albicans 
Candida, and 3 of 81 (3.7%) C. glabrata isolates were 
resistant to ketoconazole, and only one C. glabrata was 
fluconazole resistant. Also, five C. glabrata isolates 
showed susceptibility to fluconazole in a dose-
dependent manner. A previous study indicated that 
nystatin was an appropriate option instead of 
imidazoles
[33]
. An investigation from Iran found that 
clinical isolates of Candida spp. were susceptible to 
clotrimazole, miconazole, and nystatin
[19]
. Razzaghi-
Abyaneh et al.
[34]
 indicated that itraconazole was the 
most effective antimycotic drug for C. krusei, C. 
glabrata, and C. guilliermondii isolates of superficial 
candidiasis in Iran. In the current study, 26 isolates of 
C. glabrata were susceptible dose-dependent to 
fluconazole, and one isolate was resistant to 
fluconazole and clotrimazole. In addition, one isolate 
of C. lusitaniae was susceptible to fluconazole in a 
dose-dependent manner and resistance to 
clotrimazole
[35,36]
.  
The phylogenetic analyses of the D1-D2 and the ITS 
domains indicated that clinical isolates of vaginal 
candidiasis are genetically similar to reference Candida 
species. The phylogenetic analyses of the D1-D2 
domain revealed that all C. glabrata isolates had 100% 
similarity to KU729149 (ATCC 90030), KU729145 
(ATCC 66032), and KU729137 (ATCC 2001) 
reference strains. Clinical isolates of C. krusei (Pichia 
kudriavzevii) showed 100% identity with KU729202 
(ATCC 34135) and KU729201 (ATCC 14243) 
reference strains. C. kefyr (Kluyveromyces marxianus) 
and C. lusitaniae (Clavispora lusitaniae) were similar 
to KM279378 (isolate U-MF11) and KP070758 
(isolate 0Q10) reference strains, respectively. Based on 
the phylogenetic analyses of the ITS region, C. 
glabrata clinical isolates showed similarity to 
KP675206 (strain m36b), KP131703 (CNRMA6.53 
isolate ISHAM-ITS_ID MITS649), KP675517 (strain 
M310B), and LT577613 (strain IQBasrah28) reference 
strains in the GenBank databases. C. krusei (Pichia 
kudriavzevii) showed similarity to KX833111 (strain 
DMic 165166) and KX015902 reference strains.  
C. kefyr (Kluyveromyces marxianus) amplified 
sequences matched completely with the corresponding 
sequences of the KJ849337 (strain ZT-Kma.4) and 
KJ849335 reference strains. C. lusitaniae (Clavispora 
lusitaniae) indicated 96% identity with KP674503 
(strain B157B) reference strain. The phylogenetic trees 
were created using the sequences of different Candida 
clinical isolates and showed the formation of separate 
branches for each species. 
Sequencing of the ITS region and D1-D2 domain 
appears to be the most effective method for 
identification of Candida spp. The phylogenetic trees 
based on sequences of D1-D2 and ITS domains 
showed similarity of Candida spp. to closely related 
reference species. Results suggested that amphotericin 
B and itraconazole retain good clinical effectiveness. 
Accurate identification and assessment of susceptibility 
of Candida spp. isolates are critical to treatment 
management, since some strains showed varying 
degrees of resistance to antifungal drugs. 
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